Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "N03AE01" (6)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Clonazepam (N03AE01) 6 products
WHO-DDD
DrugBank.ca
IP
CI
Clonazepam Rivopharm 0,5 mg
50
PR
PR
k.A.
Tablets: Clonazepamum
Rivopharm SA
B
FB
G
IP
Clonazepam Rivopharm 2 mg
100
PR
PR
k.A.
Tablets: Clonazepamum 2 mg
Rivopharm SA
B
FB
G
IP
CI
A
Rivotril 0.5 mg
50 Tablet(s)
2.18
11.60
10 %
Tablets: Clonazepamum
Cheplapharm Schweiz
GmbH
B / SL
FB
G
IP
CI
A
Rivotril 2 mg
100 Tablet(s)
8.01
25.15
10 %
Tablets: Clonazepamum 2 mg
Cheplapharm Schweiz
GmbH
B / SL
FB
G
IP
CI
A
Rivotril
5 ampoule(s)
3.96
13.55
10 %
Konzentrat und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung: Clonazepamum 1 mg
Cheplapharm Schweiz
GmbH
B / SL
FB
G
IP
CI
A
Rivotril
10 ml
3.20
12.70
10 %
Tropfen zum Einnehmen: Clonazepamum 2.5 mg/ml
Cheplapharm Schweiz
GmbH
●
B / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
